Compare Amplitude Inc (AMPL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs Inovio Pharmaceuticals Inc — how do they compare? Amplitude Inc trades at $12.38 (market cap $1.59B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Amplitude Inc is far larger — about 20.2× Inovio Pharmaceuticals Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPL | INO | |
|---|---|---|
Market Cap | $1.59B | $78.55M |
Sector | Technology | Health |
52-Week High | $12.69 | $2.87 |
52-Week Low | $5.61 | $0.66 |
Enterprise Value | $1.45B | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $12.37, up 1.48% today, with a bullish technical signal from moving averages. Revenue grew to $343.21M in 2025, but net losses persist at -$88.54M. Analyst consensus is bullish with a $12.08 price target, supported by enterprise and AI-driven growth initiatives highlighted in recent earnings calls. The stock shows strong institutional buy ratings despite negative profitability metrics.
Outlook remains cautiously optimistic due to revenue growth and AI expansion, but risks include sustained losses, cash flow deficits, and ongoing legal investigations. The stock's valuation at P/S 4.49 may appeal if profitability improves, yet high P/B 11.64 signals premium pricing relative to book value.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
